These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 18364765)

  • 1. The role of MeNZB vaccination in controlling the New Zealand meningococcal epidemic.
    Lennon D
    N Z Med J; 2008 Mar; 121(1270):110-2. PubMed ID: 18364765
    [No Abstract]   [Full Text] [Related]  

  • 2. MeNZB vaccine and epidemic control: when do you stop vaccinating?
    Loring BJ; Turner N; Petousis-Harris H
    Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.
    Kelly C; Arnold R; Galloway Y; O'Hallahan J
    Am J Epidemiol; 2007 Oct; 166(7):817-23. PubMed ID: 17615088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.
    Sexton K; Lennon D; Oster P; Crengle S; Martin D; Mulholland K; Percival T; Reid S; Stewart J; O'Hallahan J
    N Z Med J; 2004 Aug; 117(1200):U1015. PubMed ID: 15475985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Invasive meningococcal infections in the Fribourg canton. Reasons for and development of a vaccination program in Gruyere in February 2001].
    Renevey F; Demierre G; Chuard C; Regamey C
    Rev Med Suisse Romande; 2001 Aug; 121(8):569-72. PubMed ID: 11565217
    [No Abstract]   [Full Text] [Related]  

  • 7. Control of epidemic group A meningococcal disease in Auckland.
    Lennon D; Gellin B; Hood D; Leach DT; Woods GM; Williams P; Thakur S; Crombie D
    N Z Med J; 1993 Jan; 106(948):3-6. PubMed ID: 8423925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy.
    Ameratunga S; Macmillan A; Stewart J; Scott D; Mulholland K; Crengle S;
    Vaccine; 2005 Mar; 23(17-18):2231-4. PubMed ID: 15755602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease.
    O'Hallahan J; McNicholas A; Galloway Y; O'Leary E; Roseveare C
    N Z Med J; 2009 Mar; 122(1291):48-59. PubMed ID: 19322255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand.
    Lennon D; Gellin B; Hood D; Voss L; Heffernan H; Thakur S
    Pediatr Infect Dis J; 1992 Aug; 11(8):617-23. PubMed ID: 1523071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
    Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E
    Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
    Bolland M
    N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
    [No Abstract]   [Full Text] [Related]  

  • 13. Nursing innovation at the heart of immunisation campaign.
    Manchester A
    Nurs N Z; 2004 Sep; 10(8):10-1. PubMed ID: 15508963
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe outbreak of meningococcal disease in Auckland.
    Jackson G; Lennon D; Voss L; Flight R
    N Z Med J; 1987 Apr; 100(821):226. PubMed ID: 3455492
    [No Abstract]   [Full Text] [Related]  

  • 15. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease.
    O'Hallahan J; Lennon D; Oster P; Lane R; Reid S; Mulholland K; Stewart J; Penney L; Percival T; Martin D
    Vaccine; 2005 Mar; 23(17-18):2197-201. PubMed ID: 15755594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.
    Dyet K; Devoy A; McDowell R; Martin D
    Vaccine; 2005 Mar; 23(17-18):2228-30. PubMed ID: 15755601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Informed choice--is the student doctor immunisation policy deficient?
    Gravatt L
    N Z Med J; 2009 Sep; 122(1302):109-10. PubMed ID: 19834530
    [No Abstract]   [Full Text] [Related]  

  • 18. Surveillance of vaccine breakthrough cases following MeNZB vaccination.
    McNicholas A; Galloway Y; Martin D; Sexton K; O'Hallahan J
    N Z Med J; 2008 Apr; 121(1272):38-46. PubMed ID: 18425153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal disease: was Ottawa's mass-vaccination program necessary?
    Gray C
    CMAJ; 1992 Mar; 146(6):1033, 1036-7. PubMed ID: 1544060
    [No Abstract]   [Full Text] [Related]  

  • 20. The use and misuse of media headlines: lessons from the MeNZB immunisation campaign.
    Turner NM; York DG; Petousis-Harris HA
    N Z Med J; 2009 Mar; 122(1291):22-7. PubMed ID: 19322252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.